Table 3.
The changes (∆) of clinical parameters from baseline to week 2 in different outcomes and treatment groups
| |
All |
Survival |
Mortality |
p |
Telbivudine |
Entecavir |
p |
|---|---|---|---|---|---|---|---|
| Patient no | 21 | 17 | 4 | 9 | 12 | ||
| ALT |
−1161 (−2313-+106) |
−1161 (−2313-+106) |
−890 (−2057- -44) |
1.000 |
−1383 (−2313-+106) |
−547.5 (−2057- -30) |
0.256 |
| Bilirubin T |
−0.4 (−9.1-+12.2) |
−1.2 (−9.1-+11.5) |
8.05 (5.9-12.2) |
0.009 |
−0.9 (−6-+11.5) |
−0.3 (−9.1-+12.2) |
0.722 |
| Creatinine |
0.22 (−0.1-+2.33) |
0.08 (−0.10-+0.87) |
0.49 (0.23-2.33) |
0.049 |
0.22 (−0.09-+0.87) |
0.27 (−0.1-+2.33) |
0.594 |
| eGFR |
|
|
|
|
|
|
|
| MDRD |
−23 (−162-+58) |
−16 (−72-+58) |
−85.5 (−162- -36) |
0.008 |
−23 (−99-+23) |
−23 (−162-+58) |
0.749 |
| CKD-EPI |
−16.1 (−65.2-+12.6) |
−6.0 (−65.2-+12.6) |
−35.5 (−51.3- -21.7) |
0.049 |
−21.1 (−65.2-+6.81) |
−13.0 (−51.3-+12.6) |
0.776 |
| INR |
−0.3 (−1.0-+0.9) |
−0.3 (−1.0-+0.9) |
−0.4 (−0.5-+0.7) |
0.318 |
−0.3 (−0.6-+0.9) |
−0.3 (−1.0-+0.7) |
0.971 |
| AFP |
151.5 (−140.7-+2326.6) |
184.2 (−110.2-+2326.6) |
−73.2 (−140.7- -5.8) |
0.057 |
184.2 (−5.8-+1385.9) |
101.2 (−140.7-+2326.6) |
0.386 |
| HBV DNA (log10 cps/ml) |
−3.27 (−5.47- -0.55) |
−3.4 (−5.5- -0.6) |
−1.4 (−1.8- -1.0) |
0.074 |
−3.4 (−5.0- -1.0) |
−3.0 (−5.5- -0.6) |
0.922 |
| MELD score | −1.0 (−11-+14) | −1.0 (−11-+14) | 0.0 (−1-+12) | 0.344 | −1.0 (−6-+14) | −0.5 (−11-+12) | 0.775 |
Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.